Shetty Vanaja Prabhakar, Mistry Nerges Furdoon, Wakade Anju Vilas, Ghate Sunil Dattatray, Capadia Gospi Dolly, Pai Vivek Vasudev
The Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai - 400 018, India.
Lepr Rev. 2013 Mar;84(1):23-40.
Multidrug therapy in leprosy has failed to eliminate the problem of persister bacilli. Clearance of bacterial antigens is extremely slow which could predispose to continued nerve damage even after release from treatment. In the present study the immunomodulatory efficacy of BCG vaccine administered post-MDT in BL-LL leprosy patients was investigated in depth with a view to determining if augmenting chemotherapy with immunotherapy would help in faster clearance of M. leprae/antigens, bring down the level of persisters and minimise the occurrence/severity of reaction and nerve damage.
This is a placebo-controlled study in treated BL-LL patients. The patients are matched with respect to age, sex, bacteriological index and history of reaction, stratified and allocated to the two groups. One group (Gr A) received two doses of BCG-MOSCOW (3-33 x 10(5) cells) and the other (Gr B) normal saline (0.85%), injected intra-dermally at 3 month intervals. The Primary outcomes assessed at the end of 6 months were bacterial/antigen clearance, lepromin conversion, granuloma clearance and the occurrence of persisters. The secondary outcomes were clinical regression, occurrence and severity of reaction and changes in nerve functions.
A total of 107 BL-LL patients comprised of 49 in Gr A and 58 in Gr B; of which 36 and 42 respectively completed the study as per protocol, and are included in the final analysis.
The study findings show that both the primary and the secondary out comes were comparable in the two groups. Two doses of BCG administered post-MDT (Gr A) did not significantly alter the level of persisters or help in hastening the bacterial/antigen clearance, clinical regression of lesions and granuloma clearance. Lepromin conversion rates were also comparable. While the frequency of lepra reaction/neuritis following the intervention was comparable, the severity of reactions was significantly higher in Gr A. On the positive side neural functions assessed by nerve conduction studies showed that deterioration of motor nerve conduction was significantly lower in the BCG arm. Since all patients developing moderate to severe reactions, immediately received a course of corticosteroids, it is possible that timely use of it might have helped.
麻风病的多药疗法未能消除持留菌问题。细菌抗原的清除极其缓慢,这可能导致即使在停止治疗后仍易发生持续性神经损伤。在本研究中,深入调查了在多药联合化疗(MDT)后给瘤型-界线类偏瘤型(BL-LL)麻风病患者接种卡介苗(BCG)疫苗的免疫调节功效,以确定免疫疗法增强化疗是否有助于更快清除麻风杆菌/抗原、降低持留菌水平并使反应和神经损伤的发生率/严重程度降至最低。
这是一项针对已接受治疗的BL-LL患者的安慰剂对照研究。患者在年龄、性别、细菌学指数和反应史方面进行匹配,分层并分配到两组。一组(A组)接受两剂莫斯科卡介苗(3 - 33×10⁵个菌细胞),另一组(B组)接受生理盐水(0.85%),每隔3个月皮内注射一次。6个月末评估的主要结局为细菌/抗原清除、麻风菌素转化、肉芽肿清除和持留菌的出现情况。次要结局为临床消退、反应的发生和严重程度以及神经功能变化。
共有107例BL-LL患者,其中A组49例,B组58例;其中分别有36例和42例按方案完成研究,并纳入最终分析。
研究结果表明,两组的主要和次要结局具有可比性。多药联合化疗后接种两剂卡介苗(A组)并未显著改变持留菌水平,也无助于加快细菌/抗原清除、病变的临床消退和肉芽肿清除。麻风菌素转化率也相当。虽然干预后麻风反应/神经炎的发生率相当,但A组反应的严重程度显著更高。从积极方面来看,通过神经传导研究评估的神经功能显示,卡介苗组运动神经传导的恶化程度显著更低。由于所有出现中度至重度反应的患者均立即接受了一个疗程的皮质类固醇治疗,及时使用皮质类固醇可能起到了帮助作用。